Hilary (NIH/NIAID) EN 4 ~_.(b) (6)>; Lerner, Andrea (NIH/NIAID) [E]
; Doepel, Laurie (NIH/NIAID) (EC) 6} >; Gilles, Sharon
b) (6); Routh, Jennifer (NIH/NIAID) [E]{- YJ:
Stover, Kathy (NIH/NIAID) [E] <_____ ©) ©)>; Law, Kim (NIH/NIAID) [E] NOLO
Lee, Kun-Lin (NIH/NIAID) [E] [I ) (>; Bushar, Nicholas (NIH/NIAID) [E]
; Schneider, Johanna (NIH/NIAID) (E) EC) >

Subject: RE: FY 2020 - COVID- 19 - Actual and Forecasted Spending - Weekly Report Ending 3/26/20

 

   

Tony,

YTD spending is $21.6M , a weekly increase of $4.0M for clinical trial site set-up for
therapeutics, further vaccine development, small animal development, and therapeutic
development (mAbs) and basic research.

Most of the $50M-$60M we listed last week we expect to be awarded before March 31. In many
cases contractors have begun work without the award so as to not stall work.

Early next week I'll provide a summary spending plan for the additional $706M that NIAID
received in the supplemental appropriation signed by the President today.

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, March 20, 2020 4:54 PM
To: Fauci, Anthony (NIH/NIAID) [EJ— 8) J >; Auchincloss, Hugh (NIH/NIAID) [E]
0) G}>; NIAID OCGR Leg <NIAIDOCGRLeg @mail.nih.gov>; McGowan, John J.
Pee 0)>; Harper, Jill (NIH/NIAID) (EJ) >; Crum,
Wayne (NIH/NIAID) [E] o>: Erbelding, Emily (NIH/NIAID) te
CGS Lane, cliff (NIH/NIAID) (€] ——_—_____ 36)
Ce: Eisinger, Robert (NIH/NIAID) (EJ~ CG]; Folkere, Greg (NIH/NIAID} (E]
CY}; Conrad, Patricia (NIH/NIAID) (EJ[ OY CF>; Marston, Hilary
(NIH/NIAID) (€] (©) C}>; Lerner, Andrea (NIH/NIAID) [E] {Oey
Doepel, Laurie (NIH/NIAID) [E] <8) ); Gilles, Sharon (NIH/NIAID) (E]
¢__o) (@}>; Routh, Tennifer (NIH/NIAID) | ________ 0) }>; Stover, Kathy
(NIH/NIAID) (€] 0) >; Law, Kim (NIH/NIAID) oe. Lee, Kun-Lin
(NIH/NIAID) [€](__ ©) (>; Bushar, Nicholas (NIH/NIAID) | OLS

Schneider, Johanna (NIH/NIAID) [E]]
Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spendine- Weekly Report Ending 3/19/20

 

(NIH/NIAID) (E]f

 

 

 

Tony,

YTD spending is $17.6M , a weekly increase of $3.5M for clinical trial site set-up, therapeutic
development (mAbs) and basic research.
